Market News AIOpen the app

Allarity Therapeutics got a new patent for stenoparib treatments, helping its research and development efforts.

TrialRead the original at SEC EDGAR
Good for ALLR

Allarity gained a U.S. patent covering its twice-daily stenoparib plan, with protection into 2045, strengthening its drug program and partner talks. The drug is still being tested, so the patent does not show it works or has FDA approval.

ALLR · Allarity Therapeutics, Inc.

AI read · Good for ALLR

The AI's read

That gives Allarity stronger protection for the dosing plan it expects to test in later trials, and may help it seek partners. But stenoparib remains in Phase 2, and the company says it still needs clinical results to support an FDA application. A patent protects an approach. It does not show that the drug helps patients.

Get alerts for ALLR

Follow Allarity Therapeutics, Inc. (ALLR) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for ALLR
Free on the App Store and Google Play, or on the web.